Minga Tite Mikobi, Koto Fridolin Kodondi Kule, Egboki Hillaire, Suzuki Kiyoshi
Altern Ther Health Med. 2014 Jan-Feb;20(1):20-6.
Individuals with sickle cell disease (SCD) in Africa have to manage most of their painful episodes at home, mainly due to insufficient medical services. In the past, the research team had observed that some individuals with SCD had experienced symptomatic improvement after administration of biofield therapy.
The research team intended to evaluate the influence of repeated administration of biofield therapy on clinical outcomes for individuals with SCD in Africa.
The research team designed a prospective, open label, nonrandomized, case-control study.
This study was performed at Le Centre de Médecine Mixte d'Anémie SS (CMMASS) in Kinshasa, Democratic Republic of Congo (DRC).
Participants were individuals with SCD who received treatments at CMMASS.
Twenty participants aged 3-36 y underwent Okada purifying therapy (OPT), a form of biofield therapy, every weekday for 1 y (OPT group). OPT was administered by certified practitioners approved by the MOA International Corporation. The research team also constructed an age- and gender-matched control group (n = 20) from regular patients at the clinic.
Participants in both groups received blood tests at baseline, after 6 mo, and at end of the 1-y intervention period. A follow-up survey was also conducted 33 mo after the 1-y administration of OPT.
The OPT group showed a significant improvement in its blood data, including hemoglobin, total bilirubin, alanine aminotransferase (ALT), creatinine, and white blood cell (WBC) count (P < .001). The control group had less improvement in hemoglobin (P < .001) and total bilirubin (P < .001) than the OPT group. Its creatinine level increased significantly (P < .001), and ALT and WBC count remained at the same level after 1 y. For the OPT group, SCD-related episodes, such as painful crises, blood transfusions, and hospitalizations, decreased more significantly than for the control group (P < .001). The follow-up survey revealed that those who continued using OPT regularly had remained in better condition for approximately 3 y after the intervention period than those who did not (P = .0014).
Repeated administration of biofield therapy is considered effective for individuals with SCD who have various symptoms, although the care given by the practitioners may have had some influence on the clinical outcomes.
非洲患有镰状细胞病（SCD）的患者大多要在家中应对疼痛发作，主要原因是医疗服务不足。过去，研究团队观察到一些患有SCD的患者在接受生物场疗法后症状有所改善。
研究团队旨在评估重复进行生物场疗法对非洲SCD患者临床结局的影响。
研究团队设计了一项前瞻性、开放标签、非随机的病例对照研究。
本研究在刚果民主共和国金沙萨的镰状细胞贫血综合医学中心（CMMASS）进行。
参与者为在CMMASS接受治疗的SCD患者。
20名年龄在3至36岁的参与者每个工作日接受冈田净化疗法（OPT），这是一种生物场疗法，持续1年（OPT组）。OPT由MOA国际公司认证的从业者实施。研究团队还从诊所的普通患者中构建了一个年龄和性别匹配的对照组（n = 20）。
两组参与者在基线、6个月后以及1年干预期结束时接受血液检测。在OPT治疗1年后33个月还进行了随访调查。
OPT组的血液数据有显著改善，包括血红蛋白、总胆红素、丙氨酸转氨酶（ALT）、肌酐和白细胞（WBC）计数（P <.001）。对照组的血红蛋白（P <.001）和总胆红素（P <.001）改善程度低于OPT组。其肌酐水平显著升高（P <.001），1年后ALT和WBC计数保持在同一水平。对于OPT组，与SCD相关的发作，如疼痛危机、输血和住院次数，比对照组减少得更显著（P <.001）。随访调查显示，在干预期后，持续定期使用OPT的人比未使用的人在大约3年内状况更好（P =.0014）。
尽管从业者提供的护理可能对临床结局有一定影响，但重复进行生物场疗法被认为对有各种症状的SCD患者有效。
